TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04698486

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperinsulinemic euglycaemic clamp
Description: Infusion of constant intravenous insulin to achieve hyperinsulinemia and concomitant infusion of glucose to maintain euglycemia (plasma glucose at 5 mM).~Infusion of palmitate and VLDL-triglyceride tracer. PET/CT scans of heart and liver, both in basal period and during intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperinsulinemic euglycaemic clamp
Description: Infusion of constant intravenous insulin to achieve hyperinsulinemia and concomitant infusion of glucose to maintain euglycemia (plasma glucose at 5 mM).~Infusion of palmitate and VLDL-triglyceride tracer. PET/CT scans of heart and liver, both in basal period and during intervention.
Study: NCT00080327

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Tablets, Oral, 2mg, Once daily, 6 weeks.
Study: NCT01841853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Senior meetings
Description: The intervention will be led by professionals such as a registered occupational therapist, a nurse, a physical therapist, and a social worker. The intervention will comprise four weekly meetings in small groups (4-6 participants) in addition to an individual follow-up home visit two to three weeks after the last senior meeting. To use groups involve the possibility of peer education where participants in a person-centeredness perspective are seen as experts on their own situation and learn from each other. The relationship between the personnel and the participants in the senior meetings can be described as a partnership. Respect for the participant and his/her values, and that the participant gets an opportunity to maintain and develop their own power over their own everyday activities will be essential in the meeting.
Study: NCT02428153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stretching exercises
Description: static stretching exercise of 5 repetitions, with a duration of 45 seconds to the right gastrocnemius muscle and dynamic stretching exercise of 5 repetitions, with a duration of 45 seconds to the cases' left gastrocnemius muscles
Study: NCT02365129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training based on recommendations for adults (WHO)
Description: The length of the trial will be 6 months. the total time of aerobic exercise in both moderate-intensity and vigorous-intensity groups will be 150 minutes/week, whereas the time needed to complete the resistance training exercises will be ≈15-30 minutes for both groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training based on recommendations for adults (WHO)
Description: The length of the trial will be 6 months. the total time of aerobic exercise in both moderate-intensity and vigorous-intensity groups will be 150 minutes/week, whereas the time needed to complete the resistance training exercises will be ≈15-30 minutes for both groups.
Study: NCT04086459

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Those receiving experimental treatment will receive 20 sessions of rTMS, stimulation protocol included 20 sessions within 30 days (once a day, 5 days/week, 4 weeks, 10 Hz frequency, pulse intensity 100% of the resting motor threshold, 50 pulses per train, inter train pause of 10 s, 40 stimulation trains, 2000 pulses/ session)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Those receiving experimental treatment will receive 20 sessions of rTMS, stimulation protocol included 20 sessions within 30 days (once a day, 5 days/week, 4 weeks, 10 Hz frequency, pulse intensity 100% of the resting motor threshold, 50 pulses per train, inter train pause of 10 s, 40 stimulation trains, 2000 pulses/ session)
Study: NCT01666600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: BIBF 1120 is given as 2 x minimal tolerated dose per day as long as as a clinical benefit is considered by the treating physician.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: 36 Gy, 2 Gy / fraction, 18 fractions
Study: NCT01635179

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cricoid pressure
Description: The patient is intubated twice, once with a cricoid pressure and once with a sham-pressure, when performing a videolaryngoscopy.
Study: NCT00754039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colesevelam HCl tablets and fenofibrate tablets
Description: Colesevelam 625 mg tablets - 6 tablets/day Fenofibrate 160 mg tablet - 1/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fenofibrate tablets and Welchol placebo tablets
Description: fenofibrate tablets 160 mg - 1/day + Welchol placebo tablets - 6/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fenofibrate tablets and Welchol placebo tablets
Description: fenofibrate 160 mg tablet - 1/day and Welchol placebo tablets - 6/day
Study: NCT04120675

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Early Harvest Extra Virgin Olive Oil
Description: Participants will take 3 tablespoons on a daily basis

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Early Harvest Extra Virgin Olive Oil
Description: Participants will take 3 tablespoons on a daily basis
Study: NCT01890005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Low dose aspirin (100 mg) starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
Study: NCT04224051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin target dose 2 g daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Abdominal aortic aneurysm surveillance
Study: NCT00489268

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HALO Ablation System
Description: Phase I: 1-2 ablation visits; Phase II 1 to 12 months: 1-2 ablation visits; Phase II 12 to 30 months: 1-3 ablation visits Phase II 55-60 months: 0-1 ablation visit~\*\*\*\*\*\*Phase I was a dosimetry study and Phase II used the preferred dose. The same intervention was used for each dose.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HALO Ablation System
Description: Phase I: 1-2 ablation visits; Phase II 1 to 12 months: 1-2 ablation visits; Phase II 12 to 30 months: 1-3 ablation visits Phase II 55-60 months: 0-1 ablation visit~\*\*\*\*\*\*Phase I was a dosimetry study and Phase II used the preferred dose. The same intervention was used for each dose.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HALO Ablation System
Description: Phase I: 1-2 ablation visits; Phase II 1 to 12 months: 1-2 ablation visits; Phase II 12 to 30 months: 1-3 ablation visits Phase II 55-60 months: 0-1 ablation visit~\*\*\*\*\*\*Phase I was a dosimetry study and Phase II used the preferred dose. The same intervention was used for each dose.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HALO Ablation System
Description: Phase I: 1-2 ablation visits; Phase II 1 to 12 months: 1-2 ablation visits; Phase II 12 to 30 months: 1-3 ablation visits Phase II 55-60 months: 0-1 ablation visit~\*\*\*\*\*\*Phase I was a dosimetry study and Phase II used the preferred dose. The same intervention was used for each dose.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HALO Ablation System
Description: Phase I: 1-2 ablation visits; Phase II 1 to 12 months: 1-2 ablation visits; Phase II 12 to 30 months: 1-3 ablation visits Phase II 55-60 months: 0-1 ablation visit~\*\*\*\*\*\*Phase I was a dosimetry study and Phase II used the preferred dose. The same intervention was used for each dose.
Study: NCT02839460

Intervention type: PROCEDURE
Intervention: Outpatient Muscle Biopsy
Description: Outpatient Muscle Biopsy involving skeletal muscle sample collected from the vastus lateralis muscle

Intervention type: PROCEDURE
Intervention: Outpatient Muscle Biopsy
Description: Outpatient Muscle Biopsy involving skeletal muscle sample collected from the vastus lateralis muscle
Study: NCT03280680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Female+male group sessions
Description: Female and male group member received separate group session on sexual and reproductive health and rights, gender, violence against women and girls, consent and choice, conflict resolution etc. Each group received 13 sessions of 2 hours over 20 months. Community mobilization and service provision for sexual and reproductive and violence against women were also provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Female group sessions
Description: Only female group member received separate group session on sexual and reproductive health and rights, gender, violence against women and girls, consent and choice, conflict resolution etc. Each group received 13 sessions of 2 hours over 20 months. Community mobilization and service provision for sexual and reproductive and violence against women were also provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Female group sessions
Description: Only female group member received separate group session on sexual and reproductive health and rights, gender, violence against women and girls, consent and choice, conflict resolution etc. Each group received 13 sessions of 2 hours over 20 months. Community mobilization and service provision for sexual and reproductive and violence against women were also provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No group sessions
Description: Community mobilization and service provision for sexual and reproductive and violence against women were also provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No group sessions
Description: Community mobilization and service provision for sexual and reproductive and violence against women were also provided.

Intervention type: OTHER
Group type: OTHER
Intervention: No group sessions
Description: Community mobilization and service provision for sexual and reproductive and violence against women were also provided.
Study: NCT03128164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-689
Description: Two strengths of HMPL-689 capsules (2.5 mg and 10 mg) will be used for clinical studies. The drug products are capsules.
Study: NCT00080327

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Tablets, Oral, 5mg, Once daily, 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Tablets, Oral, 10mg, Once daily, 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0mg, Once daily, 6 weeks.
Study: NCT02180386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patients will play a video game with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.
Description: videogame can be considered as a method of distraction.
Study: NCT04278573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Intralesional injection of 0.3 ml 40,000 IU/ml vitamin D3 into one wart

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.3 ml injection of sterilized sesame oil with no active study ingredient
Study: NCT00674531

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Artery resection
Description: Artery resection
Study: NCT02446782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: Cefazolin 2 gm administered in 100 mL normal saline (after skin sensitivity testing) 15-30 minutes before the start of the procedure. Clindamycin 900 mg to be administered if sensitivity detected to cefazolin.
Study: NCT01441414

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04856884
Description: 15 mg/kg/week intravenously \[IV\] until toxicity or disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib (AG-013736)
Description: 5 mg PO BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Axitinib (AG-013736)
Description: 5 mg PO BID
Study: NCT03319121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empirical therapy group
Description: Receive extended release lansoprazole (Dexlansoprazole, Takeda Pharmaceuticals, Japan) 60 mg daily for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guided therapy group
Description: Receive Dexlansoprazole 30 mg daily for GERD, 60 mg daily for GERD with erosive esophagitis for 8 weeks and Theophylline SR 250 mg daily for functional chest pain for 4 weeks.
Study: NCT04233580

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Amnio Excel + weekly
Description: Amnio Excel + weekly

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Amnio Excel + max every 2 weeks
Description: Amnio Excel + max every 2 weeks
Study: NCT00156130

Intervention type: RADIATION
Intervention: Conventional radiotherapy schedule
Description: 50 Gy in 25 fractions over 35 days

Intervention type: RADIATION
Intervention: Accelarated radiotherapy schedule
Description: 42.5 Gy in 16 fractions over 22 days
Study: NCT02902315

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: The intervention will consist of the application of hypothermia by immersion of the lower limbs of water on individuals to 15ºC for a period of 10 minutes immediately after the exercise protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: The intervention will consist of the application of hypothermia by immersion of the lower limbs of water on individuals to 15ºC for a period of 10 minutes immediately after the exercise protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: The intervention will consist of the application of hypothermia by immersion of the lower limbs of water on individuals to 15ºC for a period of 10 minutes immediately after the exercise protocol.
Study: NCT02446782

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: 100 mL normal saline 15-30 minutes before the start of the procedure
Study: NCT02040220

Intervention type: DRUG
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: 2 mg of Eylea will be treated per one injection at more than one months interval usually.
Study: NCT01723605

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: insitu repair
Description: closure of the uterine incision while the uterus initu

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: exteriorisation of the uterus
Description: uterine closure while the uterus is exteriorised
Study: NCT02217033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 'R' (Electro-kinetically altered beverage)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (water)
Study: NCT02038426

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: BLOOD SAMPLES

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BLOOD SAMPLES

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BLOOD SAMPLES

Intervention type: DEVICE
Group type: OTHER
Intervention: Radiographs of the sacroiliac joints

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiographs of the sacroiliac joints

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiographs of the sacroiliac joints

Intervention type: DEVICE
Group type: OTHER
Intervention: Radiographs of heels

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiographs of heels

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiographs of heels

Intervention type: DEVICE
Group type: OTHER
Intervention: SCAN

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCAN

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCAN
Study: NCT02019251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perfluorinated gas/oxygen mixture
Description: Subjects are imaged with MRI one time with the use of perfluorinated gas / oxygen mixtures as an MRI contrast agent for lung function.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study: NCT00933933

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARCHITECT HIV Ag/Ab Combo
Description: Test blood samples with investigational HIV assay. If results for specimens from the normal healthy population or pregnant female population at risk for HIV infection are reactive, samples will be tested with supplemental HIV assays. If all supplemental HIV assays are negative, subject will be asked to return for a follow-up blood draw.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARCHITECT HIV Ag/Ab Combo
Description: Test blood samples with investigational HIV assay. If results for specimens from the at risk population are reactive, samples will be tested with supplemental HIV assays. If all supplemental HIV assays are negative, subject will be asked to return for a follow-up blood draw when possible.
Study: NCT03524144

Intervention type: OTHER
Group type: OTHER
Intervention: gastroscopy
Description: Two endoscopists performed upper gastrointestinal endoscopy and biopsy on all patients; and histological review was performed by two pathologists. From each patient, 10 specimens were taken from 6 areas in the upper gastrointestinal tract and basic informations was collected.
Study: NCT00993889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR during Physical Therapy
Description: Virtual Reality will be performed during a painful physical therapy procedure.
Study: NCT04242030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moxibustion
Description: Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Heart meridian along the left forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the left forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the left forearm.

Intervention type: DEVICE
Group type: OTHER
Intervention: Laser doppler flowmetry
Description: Laser doppler flowmetry will be used to detect the microcirculatory characteristics of meridian phenomena for the Heart meridian and Lung meridians.

Intervention type: DEVICE
Group type: OTHER
Intervention: Laser doppler flowmetry
Description: Laser doppler flowmetry will be used to detect the microcirculatory characteristics of meridian phenomena for the Heart meridian and Lung meridians.
Study: NCT00993889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR Background Pain
Description: Virtual Reality is used at anytime during the day for the background pain, not during physical therapy.
Study: NCT04242030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser doppler flowmetry
Description: Laser doppler flowmetry will be used to detect the microcirculatory characteristics of meridian phenomena for the Heart meridian and Lung meridians.
Study: NCT00993889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NO VR
Description: The subject will receive the usual standard treatment. At the end of the study, before being discharged from the hospital, the subject can experience the VR, not during a procedure.
Study: NCT03752931

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celiprolol
Description: receiving 1 tablet per day of Celiprolol 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobecomty for 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem
Description: receiving 1 tablet per day of Diltiazem 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobecomty for 2 weeks.
Study: NCT01586182

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: Starting dose is 5.5 Gy x 2 boosts in addition to 57.24 Gy to the primary disease
Study: NCT02285972

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: before the anesthesia induction, 2mL saline iv injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexketoprofen
Description: before the anesthesia induction, 50 mg (2mL) iv dexketoprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenoxicam
Description: before the anesthesia induction, 20 mg (2mL) iv tenoxicam
Study: NCT04339972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIFUP
Description: Low Intensity Focused Ultrasound Pulsation (LIFUP) is an interesting new form of brain stimulation that may be possible to stimulate non-invasively, safely, deep in the brain with focal precision.
Study: NCT04180592

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Fusion + Transrectal U/S Guided Prostate Biopsy
Description: All patients will receive both a CT fusion biopsy and a standard TRUSP biopsy. They will be randomized to which is received first, followed by receipt of the alternative procedure.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CT Fusion + Transrectal U/S Guided Prostate Biopsy
Description: All patients will receive both a CT fusion biopsy and a standard TRUSP biopsy. They will be randomized to which is received first, followed by receipt of the alternative procedure.
Study: NCT00893607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001
Description: 10mg NRL001 was administered as a slow release suppository

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001
Description: 10mg NRL001 was administered as a slow release suppository
Study: NCT04278742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient education
Description: Using a collaborative approach to engage patients in their own care, allowing patients to continue to have full control of their treatment. The clinician and patient co-creates the treatment plan.
Study: NCT03432286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SQ

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SQ